Effect of Tetrabenazine on Motor Function in Patients with Huntington Disease

Neurology and Therapy

Volumn 1, Issue 1, 2012, Pages 1-8

  Ferrara, Joseph M ^a   Mostile, Giovanni ^b   Hunter, Christine ^b   Adam, Octavian R ^c   Jankovic, Joseph ^b  

^a VIRGINIA TECH CARILION SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Naval Reserve Naval Medical Center   (United States)

Author keywords

Berg Balance Scale; Chorea; Huntington disease; Jebsen Taylor Hand Function Test; Tetrabenazine

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; TETRABENAZINE;

ADULT; AGED; ARTICLE; BERG BALANCE SCALE; CLINICAL ARTICLE; FATIGUE; FEMALE; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; INSOMNIA; JEBSEN TAYLOR HAND FUNCTION TEST; MALE; MONTREAL COGNITIVE ASSESSMENT; MOTOR PERFORMANCE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; SCORING SYSTEM; UNIFIED HUNTINGTON DISEASE RATING SCALE;

EID: 84977083782     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-012-0005-7     Document Type: Article

References (24)

1. Fenney A, Jog MS, Duval C. Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology. Brain Res. 2008;1193: 67-75.
2. Reilmann R, Kirsten F, Quinn L, Henningsen H, Marder K, Gordon AM. Objective assessment of progression in Huntington's disease: a 3-year follow-up study. Neurology. 2001;57: 920-4.
3. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66: 366-72.
4. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11: 136-42.
5. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009;9: 62.
6. Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil. 1969;50: 311-9.
7. Berg KO, Maki BE, Williams JI, Holliday PJ, Wood-Dauphinee SL. Clinical and laboratory measures of postural balance in an elderly population. Arch Phys Med Rehabil. 1992;73: 1073-80.
8. Lynch DR, Farmer JM, Wilson RL, Balcer LJ. Performance measures in Friedreich ataxia: potential utility as clinical outcome tools. Mov Disord. 2005;20: 777-82.
9. Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM. The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord. 2010;25: 401-4.
10. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006;6: 7-17.
11. Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002;25: 300-2.
12. Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007;22: 10-3.
13. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5: 181-97.
14. Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008;31: 127-33.
15. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8: 844-56.
16. Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington's disease: which factors matter most? Mov Disord. 2009;24: 574-8.
17. Marder K, Zhao H, Myers RH, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000;54: 452-8.
18. Feigin A, Kieburtz K, Bordwell K, et al. Functional decline in Huntington's disease. Mov Disord. 1995;10: 211-4.
19. Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry. 2003;74: 120-2.
20. Delval A, Krystkowiak P, Delliaux M, et al. Role of attentional resources on gait performance in Huntington's disease. Mov Disord. 2008;23: 684-9.
21. Rodrigues GR, Souza CP, Cetlin RS, et al. Use of the frontal assessment battery in evaluating executive dysfunction in patients with Huntington's disease. J Neurol. 2009;256: 1809-15.
22. Thompson JC, Poliakoff E, Sollom AC, Howard E, Craufurd D, Snowden JS. Automaticity and attention in Huntington's disease: when two hands are not better than one. Neuropsychologia. 2010;48: 171-8.
23. Cubo E, González M, Del Puerto I, FernándezArconada O, Garcia de Yebenes J. Impact of placebo treatment in Huntington's disease: P05. 025. Neurology. 2010;74(Suppl. 2): A413.
24. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther. 1959;127: 103-9.